Tifacogin for CAP?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron is planning a Phase III trial of tifacogin for severe community-acquired pneumonia. Development for severe sepsis, in collaboration with Pharmacia, was suspended in November 2001 because the tissue factor pathway inhibitor failed to meet its primary endpoint of 28-day all cause mortality. Chiron has acquired all of Pfizer's interest in tifacogin; Pfizer will receive royalties on tifacogin sale